Thymomas are tumors arising from the epithelial cells of the thymus, the organ behind the breastbone where immune cells called T lymphocytes mature. In goats, the thymus has paired cranial and cervical lobes plus a single thoracic lobe, and tumors can develop in the cranial mediastinum, the space between the lungs, or in the ventral neck region. Post-mortem surveys suggest thymomas make up roughly ten percent of all tumors in goats, and dairy breeds such as Nigerian Dwarf and Saanen may carry an even higher prevalence, with one classic study reporting rates as high as twenty-five percent. Despite how common they appear to be at necropsy, almost nothing has been published about actually treating them.

The goat arrived at the University of Florida Large Animal Hospital after several days of lethargy, fever, and reduced appetite. On examination she was febrile at 106.2 degrees Fahrenheit, with rapid heart and respiratory rates, hyperemic mucous membranes, poor rumen contractions, and a heart murmur. Bloodwork revealed elevated fibrinogen and creatine kinase, low protein and calcium, and abnormalities on venous blood gas. A point-of-care thoracic ultrasound uncovered the likely culprit: a mass in the cranial mediastinum, alongside B-line artifacts and small areas of consolidation in the front of the chest that pointed to pneumonia.

A computed tomography scan performed under general anesthesia characterized the mass in detail. It measured 8.6 by 6.5 by 6 centimeters, appeared heterogeneous in soft tissue and fluid attenuation, and enhanced strongly with contrast. The tumor was displacing the cranial vena cava caudodorsally, pushing the heart backward, and compressing the cranial lung lobes, but there was no vascular invasion. Ultrasound-guided fine-needle aspiration yielded lymphoid tissue with poorly preserved epithelial cell aggregates and occasional mast cells, findings most consistent with a neoplasm of thymic origin, suspected to be a thymoma. The team also identified patterns consistent with aspiration or chronic bronchopneumonia and treated the goat empirically with florfenicol.

Treatment options were weighed carefully with the owner. Surgical excision was declined because of the substantial risk of intraoperative hemorrhage, a complication that has proven fatal in the only two goats previously reported to undergo thoracic surgery for mediastinal thymoma. Radiation therapy was offered instead, with candid discussion of acute risks including pneumonitis, esophagitis, tracheitis, and myocarditis, and late risks such as cardiomyopathy, arrhythmia, and lung fibrosis. The owner elected a palliative-intent protocol of four weekly fractions of 8 Gy, totaling 32 Gy, a schedule chosen to reduce costs and minimize the number of hospital visits and anesthetic episodes.

The technical execution of the plan illustrates how far veterinary radiation oncology has come. The goat was positioned in sternal recumbency in a vacuum-sealed cushion for a planning CT scan. The contrast-enhancing mass was contoured as the gross tumor volume, expanded uniformly by 2 millimeters to create the planning target volume. Because thymomas typically move little with respiration, no internal target volume was used, and the small margin prioritized sparing nearby organs at risk: the lungs, heart, esophagus, trachea, and spinal cord. An inverse-planned intensity-modulated plan with eight coplanar isocentric beams was generated on the Eclipse planning system, normalized so that 95 percent of the target received the full prescription dose, with only 5.6 percent of lung volume receiving 20 Gy or more.

Quality assurance was rigorous. The plan was verified with a two-dimensional diode array, requiring at least 95 percent of measured points to agree with the calculated fluence at a 3 percent and 3 millimeter criterion. Treatment was delivered with 6 MV photons from a Varian Edge linear accelerator equipped with a 120-leaf multileaf collimator, and cone-beam CT scans taken before each session confirmed accurate positioning. Each fraction required general anesthesia, induced with propofol after butorphanol and midazolam premedication and maintained on isoflurane, with no complications. By the fourth fraction, the cone-beam CT already showed the tumor shrinking by roughly 5 millimeters in every dimension, and the goat’s appetite had returned to normal while her heart murmur had quieted.

The response endured. A recheck CT scan four months after treatment, performed during an unrelated emergency visit for fever and lethargy, showed the mass had shrunk to 6 by 4.6 by 5.2 centimeters, a 30 percent reduction that meets the formal definition of a partial response under Veterinary Cooperative Oncology Group RECIST criteria. The pulmonary changes seen before treatment had nearly resolved. A scan at ten months confirmed a persistent partial response, though it also revealed mild progression of lower airway inflammation and bronchopneumonia that the authors could not rule out as a low-grade late radiation effect or unrelated chronic bronchitis. Twenty months out, the owner reported only occasional mild coughing, and the goat was still alive at the time of manuscript submission, roughly 1,230 days after treatment began.

The result carries weight because the comparative literature is so thin. Only one previous goat with a cranial mediastinal thymoma had been treated with radiation, receiving 32 Gy in 4 Gy fractions every other day, with tumor regression noted by the sixth fraction and survival of at least 1.5 years. In dogs and cats, surgery remains the treatment of choice for thymoma, though perioperative mortality approaches 20 percent, and radiation produces overall response rates of 33 to 75 percent with median survival times of 5 to 8 months in dogs and 24 months in cats. Because metastasis is rarely seen in caprine thymoma, local control is the central therapeutic goal in goats as well, making radiation an attractive alternative when thoracic surgery is too risky or unavailable.

The authors acknowledge limitations, most notably that the diagnosis rested on cytology rather than the histopathology required for definitive confirmation of thymoma. They also note that the link between the goat’s pneumonia and the tumor is uncertain; in dogs, thymoma-associated megaesophagus drives aspiration pneumonia, but myasthenia gravis appears far less common in goats, and no megaesophagus was seen on CT. Still, the message is clear. As goats increasingly live as companion animals rather than production livestock, cancer care becomes a relevant expectation for their owners, and this case demonstrates that modern, image-guided, hypofractionated radiation therapy is technically feasible in goats, was well tolerated, and can produce objective, durable tumor shrinkage. Larger cohorts will be needed before firm recommendations can be made, but for pet goats facing inoperable mediastinal thymoma, radiation therapy now stands as a legitimate option to discuss.

Subject of Research: Palliative hypofractionated image-guided intensity-modulated radiation therapy for a cranial mediastinal thymoma in a Nigerian Dwarf goat

Article Title: Image-guided intensity-modulated radiation therapy for a mediastinal thymoma in a Nigerian Dwarf goat: a case report

Article References: Argenti, T., Jodzio, D., Hancock, K., Darby, S., Luethy, D., Gilor, S., Gutti, J., & Takada, M. (2026). Image-guided intensity-modulated radiation therapy for a mediastinal thymoma in a Nigerian Dwarf goat: a case report. Veterinary Oncology, 3(1), Article 4. https://doi.org/10.1186/s44356-026-00055-6

Image Credits: AI Generated

DOI: 10.1186/s44356-026-00055-6

Keywords: thymoma, goat, radiation therapy, IMRT, veterinary oncology, Nigerian Dwarf goat, mediastinal mass, hypofractionated radiation, computed tomography, palliative care, caprine neoplasia, partial response

The numbers behind the warning are sobering. The overall incidence of checkpoint inhibitor-associated myocarditis ranges from 0.3 percent to 2.2 percent, with severe disease, graded 3 or higher on the Common Terminology Criteria for Adverse Events version 5.0, accounting for 0.15 percent to 0.69 percent of treated patients. Mortality remains stubbornly high at 37 to 50 percent, and combination immunotherapy is more dangerous than monotherapy, with reported death rates of 66 percent versus 44 percent. A Chinese cohort of 55,219 patients with advanced non-small cell lung cancer found an annual incidence of 0.51 percent for PD-1 inhibitor-associated myocarditis, or 5.1 cases per 1,000 person-years, underscoring that the threat scales with the enormous and growing global use of these drugs.

Combination regimens are a central theme of the new guidance. A French nationwide database analysis showed that the six-month cumulative incidence of myocarditis reached 1.6 percent for PD-1 plus CTLA-4 inhibitor combinations, compared with 0.2 to 0.4 percent for monotherapy. In a large retrospective cohort of 53,018 patients, combination therapy carried a hazard ratio of 2.92 for myocarditis relative to monotherapy. Pharmacovigilance data drawn from 171,132 case reports in the United States Food and Drug Administration safety database identified 1,326 myocarditis cases across nine checkpoint inhibitors, with a reporting odds ratio of 30.1 overall, and the signal for PD-L1 plus CTLA-4 combination therapy was more than double that of PD-L1 monotherapy. The 2026 recommendations also extend their scope to newer agents, including the PD-1/CTLA-4 bispecific antibodies cadonilimab and iparomlimab/tuvonralimab, the PD-1/VEGF bispecific antibody ivonescimab, and other novel constructs now approved in China, reflecting emerging evidence on cardiac injury linked to bispecific antibodies.

Among the most striking updates is the formal incorporation of thymic imaging into risk stratification. Patients with thymic epithelial tumors, particularly thymoma, face dramatically elevated risk: one analysis found an odds ratio of 32 for myocarditis in thymoma patients, while a meta-analysis showed myocarditis rates of 29 percent in thymoma versus 2 percent in thymic carcinoma. These patients also develop myocarditis earlier, with a median time to onset of 21 days compared with 41 days for other cancers, and suffer more life-threatening arrhythmias, more concomitant myositis and myasthenia gravis-like syndromes, and higher 30-day mortality. A multicenter study established a thymic grading system based on chest computed tomography, finding that a pretreatment thymic grade of 3 or higher, indicating a solid component above 50 percent, was far more common in patients who went on to develop myocarditis, with an odds ratio of 25. Acetylcholine receptor antibody positivity, a marker of thymus-associated autoimmunity, was also significantly more frequent in affected patients and predicted early cardiotoxic events.

The recommendations therefore advise that before starting checkpoint inhibitors, all patients undergo baseline evaluation including family and personal history, biomarkers of myocardial injury, electrocardiography and echocardiography. For patients with a history of thymic tumors or suspected thymic abnormalities, chest CT is recommended to assess thymic size, morphology and density, along with acetylcholine receptor antibody testing when autoimmune thymic disease is suspected. Those with residual thymic tissue, abnormal ovoid thymic morphology or abnormal mediastinal fat attenuation should be evaluated by a multidisciplinary cardio-oncology team to weigh the benefit-risk ratio and design individualized monitoring. Coexisting autoimmune disease is not an absolute contraindication to immunotherapy, but the panel recommends assessing disease activity first, coordinating with rheumatology, and keeping baseline immunosuppression at the lowest effective dose, ideally no more than 10 milligrams per day of prednisone equivalent. Routine prophylactic glucocorticoids to prevent immune-related adverse events are explicitly not recommended, because baseline immunosuppression has been associated with shorter survival and higher relapse of underlying autoimmune disease.

Once therapy begins, the guidance prescribes an intensive early monitoring schedule built around the observation that most myocarditis cases strike within the first three months, with median time to onset of 28 to 65 days across studies. For patients treated every two weeks, symptom assessment, electrocardiography and cardiac troponin testing are recommended before cycles 2 through 9; for three-week schedules, before cycles 2 through 6. Biomarker data show why vigilance matters: in hospitalized patients, cardiac troponin T was elevated in 98 percent, troponin I in 88 percent and creatine kinase in 75 percent, and troponin T proved the most sensitive early marker, remaining elevated for months while other markers normalized faster. Baseline troponin T at twice the upper reference limit carried a hazard ratio of 31.71 for subsequent myocarditis in one prospective cohort. Electrocardiographic changes also carry prognostic weight, with new QRS widening beyond 110 milliseconds associated with a more than threefold increase in major adverse cardiac events.

Diagnosis follows a hierarchical framework anchored either by histopathology or by clinical criteria. Endomyocardial biopsy remains the gold standard, revealing multifocal inflammatory infiltration dominated by CD8-positive T lymphocytes with significant cardiomyocyte loss, but the panel individualizes its use given sampling error and procedural risk. Without biopsy, diagnosis requires elevated troponin, preferably troponin T, plus either one major criterion, cardiac magnetic resonance findings meeting the modified Lake Louise criteria with evidence of myocardial edema on T2 mapping and non-ischemic injury on T1 mapping, or at least two minor criteria such as a compatible clinical syndrome, ventricular arrhythmias or conduction abnormalities, reduced left ventricular function, concurrent immune-related adverse events like myositis or myasthenia gravis, or partially concordant cardiac magnetic resonance findings. The panel cautions that conventional cardiac magnetic resonance has limited early sensitivity: late gadolinium enhancement was detected in only 48 percent of cases overall and just 21.6 percent within four days of admission, so quantitative T1 and T2 mapping and, in selected cases, positron emission tomography with tracers such as 18F-FDG, 68Ga-DOTATOC or 68Ga-FAPI can provide complementary information. Differential diagnosis must exclude infectious myocarditis, acute coronary syndrome, Takotsubo cardiomyopathy, pulmonary embolism and tumor progression, with coronary angiography reserved for ST-elevation patterns.

Treatment hinges on speed and severity stratification. Once myocarditis is confirmed, checkpoint inhibitor therapy is stopped immediately and glucocorticoids started, ideally within 24 hours of symptom onset; a multicenter study of 126 patients showed that steroids begun within 24 hours significantly reduced peak troponin compared with later initiation, and high-dose regimens of 501 to 1,000 milligrams per day of methylprednisolone were associated with a major adverse cardiac event rate of 22 percent versus 54.6 to 61.9 percent with lower doses. Occult subclinical injury warrants observation or modest prednisone dosing, mild disease calls for 1 to 2 milligrams per kilogram per day of methylprednisolone, severe disease requires 500-milligram pulse therapy plus intravenous immunoglobulin at 0.4 grams per kilogram daily, and critical disease demands intensive care, 500 to 1,000 milligram daily pulses, immunoglobulin, immediate second-line immunosuppression and life support including temporary pacing, plasma exchange and mechanical circulatory support. Steroid resistance, defined by failure of troponin to fall by at least half or persistence of conduction block, arrhythmias or ventricular dysfunction after three days, triggers escalation to agents such as abatacept, antithymocyte globulin, mycophenolate mofetil, tacrolimus, the JAK inhibitors tofacitinib and ruxolitinib, or biologics including tocilizumab and alemtuzumab, with infliximab used cautiously given signals of increased cardiovascular death. Notably, a prospective strategy combining high-dose abatacept with ruxolitinib and glucocorticoids cut mortality to 3 percent versus 60 percent with high-dose steroids alone, and randomized trials including ATRIUM and ACHLYS are now testing abatacept as initial therapy.

Recovery does not end the story. The panel recommends weekly monitoring of symptoms, electrocardiography and troponin during steroid tapering over roughly four to six weeks, followed by visits every two to three weeks for three months after discontinuation, since troponin T can remain elevated for months and late cardiac events still occur. Resumption of immunotherapy is reserved for fully resolved, biologically recovered disease, defined as normalized troponin T and complete steroid withdrawal, and is generally limited to patients with occult or mild initial episodes; severe or critical myocarditis mandates permanent discontinuation. When rechallenge is unavoidable and no alternatives exist, the decision should be made jointly by cardiology and oncology, with de-escalation from combination therapy to PD-1 or PD-L1 monotherapy and intensified biomarker surveillance, acknowledging that roughly a third to half of rechallenged patients experience recurrent immune-related adverse events. Looking ahead, the guidelines highlight artificial intelligence-assisted early screening, machine learning risk scores integrating baseline characteristics and treatment regimens, and multimodal imaging analytics as promising tools to catch this elusive, fast-moving complication before it becomes fatal, while emphasizing that multidisciplinary cardio-oncology collaboration remains the backbone of safe immunotherapy.

Subject of Research: Clinical diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis

Article Title: Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-associated myocarditis (2026 edition)

Article References: Yan, W., Qingqing, C., Yuan, L., Jiahui, C., Hao, L., Jinyi, L., Zhiming, W., Yinman, W., Zhifeng, Y., Shilong, Z., Lingying, M., Ji, Z., Shufu, C., Chi, Z., Rongle, L., Xin, Z., Cong, W., Xianling, Q., Zheng, L., … Junbo, G. (2026). Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-associated myocarditis (2026 edition). Clinical Cancer Bulletin, 5(1), Article 13. https://doi.org/10.1007/s44272-026-00065-3

Image Credits: AI Generated

DOI: 10.1007/s44272-026-00065-3

Keywords: immune checkpoint inhibitors, myocarditis, cardio-oncology, immunotherapy toxicity, glucocorticoids, abatacept, cardiac troponin, thymoma, cardiac magnetic resonance, bispecific antibodies, immunosuppression, clinical guidelines